Trends in Malignant Glioma Monoclonal Antibody Therapy
Trends in Malignant Glioma Monoclonal Antibody Therapy
复制标题
DOI：
10.2174/1573394711888150917142941
复制
发表时间：
2015-06
影响因子：
4.1
通讯作者：
Gurina O
中科院分区：
文献类型：
--
作者：
Chekhonin I;Gurina O
虽然新的被动和主动免疫治疗方法不断出现，但非偶联单克隆抗体仍然是临床上唯一被批准用于高级别胶质瘤治疗的生物制剂。本文就联合收割机的临床和实验数据进行综述。由于抗血管生成治疗是复发性多形性胶质母细胞瘤（GBM）的标准治疗，我们分析了贝伐单抗（最常见的血管内皮生长因子（VEGF）单克隆抗体）的主要临床试验和可能的治疗组合。另一种在GBM中获得识别的人源化抗体是表皮生长因子（EGFR）拮抗剂尼妥珠单抗。其他抗原（VEGF受体，血小板衍生生长因子受体，肝细胞生长因子和c-Met系统）在胶质瘤中显示出显著性，并用于创建应用于不同恶性肿瘤的单克隆抗体。我们评估遗传标记（异柠檬酸脱氢酶，O 6-甲基鸟嘌呤-DNA甲基转移酶）在GBM治疗结果预测中的作用。除了在临床试验中研究的抗体外，我们还重点关注了前瞻性靶点，并简要列出了被动免疫治疗的其他方法。
Although new passive and active immunotherapy methods are emerging, unconjugated monoclonal antibodies remain the only kind of biological preparations approved for high-grade glioma therapy in clinical practice. In this review, we combine clinical and experimental data discussion. As antiangiogenic therapy is the standard of care for recurrent glioblastoma multiforme (GBM), we analyze major clinical trials and possible therapeutic combinations of bevacizumab, the most common monoclonal antibody to vascular endothelial growth factor (VEGF). Another humanized antibody to gain recognition in GBM is epidermal growth factor (EGFR) antagonist nimotuzumab. Other antigens (VEGF receptor, platelet-derived growth factor receptor, hepatocyte growth factor and c-Met system) showed significance in gliomas and were used to create monoclonal antibodies applied in different malignant tumors. We assess the role of genetic markers (isocitrate dehydrogenase, O6-methylguanine-DNA methyltransnsferase) in GBM treatment outcome prediction. Besides antibodies studied in clinical trials, we focus on perspective targets and briefly list other means of passive immunotherapy.